Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
about
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxisNonoccupational postexposure prophylaxis following sexual assault in industrialized low-HIV-prevalence countries: A reviewEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenPractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewEfficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate StudiesNeedlestick and Sharps Injuries in Dermatologic Surgery: A Review of Preventative Techniques and Post-exposure ProtocolsAntiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisPrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirSystemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT micePharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionCan antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activationAntiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and disseminationBiomedical prevention: state of the science.Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisSexual assault: a report on human immunodeficiency virus postexposure prophylaxis.Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trialFactors Associated With Forensic Nurses Offering HIV nPEP Status Post Sexual Assault.Current perspectives in HIV post-exposure prophylaxis.Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers)Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measuresNonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques.Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.Acute HIV revisited: new opportunities for treatment and prevention.Awareness and low uptake of post exposure prophylaxis for HIV among clinical medical students in a high endemicity setting.Nonoccupational Postexposure Human Immunodeficiency Virus Prophylaxis: Acceptance Following Sexual AssaultPost exposure prophylaxis of HIV transmission after occupational injuries in Queen Elizabeth Central Hospital, Blantyre, Malawi, 2003 - 2008.Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocDevelopment of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3)A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infectionGender Reassignment Surgery in Human Immunodeficiency Virus-Positive Patients: A Report of Two CasesHuman immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.Vaginal microbicides and the prevention of HIV transmissionThe pharmacokinetics and viral activity of tenofovir in the male genital tractHIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.Attitudes toward Web application supporting pharmacist-clinician comanagement of postexposure prophylaxis patients.
P2860
Q22242951-E7452A84-B347-4EDB-8FD7-5BD3182015C9Q22248015-F3E78C4E-1F02-4462-B7CB-4E961C3FCD0FQ24629582-F74E2969-CF35-4097-B7FA-0F88C9376C95Q26853055-0442C231-6D5F-46DD-8D6F-58F2F095ED41Q27021082-95845167-E6B2-4BB2-A8EC-CA14A9C2D41AQ28080029-04C880F9-D833-4782-8500-DB6DEB9D6E88Q28085433-7A87591F-1D42-4AF5-A215-AD5EA534779CQ28472146-19E542C0-01EF-4244-9B4E-C1E649FF621AQ28472590-51BD8574-42EB-4F97-B31E-8673E8EECD1FQ28481276-5F13BE9F-1D73-46FF-9BC6-93D74E4842FFQ30330238-38656A35-C0F3-4F4C-AB23-7A5072D4B19DQ30362325-2D11ABB3-4035-4F3E-9AD2-06F83D7D51A1Q33582077-CCCB7D67-C5A3-4930-90F7-EDB3C5EB1B46Q33765795-E0837A61-2E90-4C18-9090-E0377F67AAA1Q33821257-2EAF3DC5-9AE6-42B6-8961-CD73EE99A580Q34034799-505A1CF6-B7CE-4E25-BD54-C1A26E1222CAQ34070706-9446704A-B173-4AE8-AA55-942667915A02Q34152689-3178D136-B0FF-4AA2-AB27-E85B2C1E5D10Q34339361-83AF94D9-FF6B-4F62-BCE6-3AEAA167C617Q34434815-61714092-DF58-4FC1-8A37-23E8D723BBDDQ34619859-2DD5DB97-BFC4-4B01-993A-81FAC5AED95FQ34675000-C35EF76B-1EDE-4FF2-9B45-307A165F1EDFQ34976172-65E8E4CC-C5E8-44C3-8616-B01E364384C7Q35558216-20365302-A6CE-4968-AAAC-CCA99AABA924Q35558801-17BF3911-5B67-4C04-9630-0E95A9EABFB0Q35696557-41F99AFF-51B1-40B5-A349-B223249ED8D8Q35730339-7DBE6640-A086-478C-B96F-25373AAF10F1Q35834660-3F5A8DCD-4F79-439C-983B-F514C26A9A19Q35866465-EAB6FADC-DBCC-4D0D-BD04-72A53F13B5E5Q35938210-CA87E46E-33D6-4077-A557-6DBC92BC94BFQ35996420-5FD7F1AF-7BA3-425D-A344-1C182474DB92Q36108441-7D8AEE6E-ADC6-4B88-B377-7CDB0E4D9D07Q36286901-F133F145-7D8E-44B7-8EBE-26534E695B63Q36320237-861367F4-C3CD-4470-B1BC-FFC4C5857F74Q36744775-F61B3DB9-F1BE-4FAA-9ED1-C0E06DCABF94Q36829666-1CB2112F-AD4B-480A-ACFB-DEF891E5E575Q37063819-181A1D8E-EDD5-4410-B19C-2C14248BBD4CQ37304746-DB0D1688-77A1-4063-8127-9DCB2F886482Q37353723-DC7C8B36-8679-495D-A809-91F5E5C297D0Q37507747-0E84ACF6-9948-43E8-9252-D1E111D8A524
P2860
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@ast
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@en
type
label
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@ast
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@en
prefLabel
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@ast
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@en
P2093
P2860
P1433
P1476
Efficacy of postexposure proph ...... mmunodeficiency virus type 2).
@en
P2093
J K Pullium
P2860
P304
P356
10.1128/JVI.74.20.9771-9775.2000
P577
2000-10-01T00:00:00Z